Keywords: Multople sclerosis, USA, Neurologists views, Biogen Idec, Elan, Novartis, Tysabri, Gilenya, Aubagio, Sanofi, Roche, Declizumab, Ocrelizumab
Despite likely new MS drugs, US neurologists continue to see significant near-term growth for Tysabri and Gilenya
Article | 01 July 2012
Within the multiple sclerosis treatment arena, the availability of the anti-JC virus antibody assay appears to be contributing to the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
